Beta Bionics (NASDAQ:BBNX) Stock: Insider Mark Hopman Sells 821 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 821 shares of Beta Bionics stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $20.00, for a total transaction of $16,420.00. Following the completion of the sale, the insider owned 54,513 shares in the company, valued at approximately $1,090,260. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The shares were sold at an average price of $17.35, for a total transaction of $13,446.25.
• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total transaction of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The stock was sold at an average price of $20.13, for a total transaction of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Stock Performance

Shares of BBNX traded down $3.54 during mid-day trading on Wednesday, reaching $17.85. 2,462,073 shares of the company’s stock traded hands, compared to its average volume of 1,183,075. The business’s 50-day moving average price is $19.23 and its 200-day moving average price is $14.97. The stock has a market capitalization of $803.07 million, a P/E ratio of -10.82 and a beta of 3.39. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The business had revenue of $35.51 million during the quarter. Equities research analysts anticipate that Beta Bionics, Inc. will post -2.02 EPS for the current year.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics reported third-quarter 2026 revenue of approximately $35.5 million, ahead of the roughly $34.7 million analyst estimate. The company’s adjusted loss of $0.52 per share also narrowly beat the consensus estimate of a $0.53 loss. Beta Bionics Q3 earnings report
• Neutral Sentiment: Multiple law firms are publicizing a November 3, 2026 deadline for investors to seek appointment as lead plaintiff in the pending litigation. The case covers investors who purchased Beta Bionics securities from July 30, 2025, through February 24, 2026. These notices are largely duplicative and do not represent separate lawsuits or new operating developments. Class action deadline notice
• Negative Sentiment: The complaint alleges that Beta Bionics and certain executives misled investors about the safety, efficacy, and commercial performance of its iLet medical device. Reported allegations include failure to disclose a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints. The allegations have not been proven, but they raise potential regulatory, product-liability, litigation-cost, and reputational risks. Beta Bionics securities-fraud lawsuit report
• Negative Sentiment: The lawsuit follows a reported collapse of more than 37% in BBNX, with legal notices linking successive disclosures about the iLet device to a cumulative $23.09 per-share decline. Continued litigation headlines and uncertainty around product safety may keep volatility elevated and weigh on investor sentiment. Beta Bionics investor class action report

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BBNX shares. Barclays began coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price target for the company. Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Bank of America raised their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. TD Cowen lifted their price objective on shares of Beta Bionics from $18.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, Jefferies Financial Group began coverage on shares of Beta Bionics in a research note on Monday, October 12th. They set a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.69.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BBNX. BlackRock Inc. bought a new position in shares of Beta Bionics in the second quarter valued at approximately $52,340,000. Eversept Partners LP raised its holdings in Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares in the last quarter. Bruce & Co. Inc. acquired a new stake in Beta Bionics in the first quarter worth approximately $5,518,000. Bank of America Corp DE acquired a new stake in Beta Bionics in the second quarter worth approximately $8,566,000. Finally, Y Intercept Hong Kong Ltd lifted its position in Beta Bionics by 4,236.8% in the first quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock worth $4,868,000 after purchasing an additional 474,651 shares during the period.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.